glp-1 vs sglt2 weight loss Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study Weight loss variability with SGLT2

Guanosine and uroguanosine, which target guanosine cyclase (GC-C) receptors in the intestine and kidney, lead to elevated intracellular cGMP concentrations, and high GC-C expression in L cells is associated with regulation of GLP-1 release (Friedlander et al., 2011)

GLP-1 Coverage and Cost Transparency for Members and Plans The GLP-1 boom illustrates how difficult it can be to predict and prepare for a sudden surge in utilization and costly claims, or the next shortage

The American Diabetes Association (ADA) recommends GLP-1 RAs in patients with clinical characteristics like presence of established ASCVD and cardiac heart failure or chronic kidney diseases [15]

Promoting satiety: GLP-1 signals the brain to reduce appetite, helping you feel satisfied and less likely to overeat

Dias-Junior et al